Tango Therapeutics, Inc. Income Statement
TNGX / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Tango Therapeutics, Inc. reported $62M in revenue and $102M in net loss for FY2025. Revenue has grown at a 52.1% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $37.0M | $7.7M | $7.7M |
| SG&A Expense | $41.5M | $43.7M | $35.5M | $17.6M | $9.9M | $9.9M |
| R&D Expense | $132.2M | $143.9M | $115.2M | $77.6M | $50.0M | $50.0M |
| Operating Income | -$111.3M | -$145.6M | -$114.2M | -$58.2M | -$52.2M | -$52.2M |
| Interest Expense | - | - | - | $495.0K | $108.0K | $108.0K |
| Income Tax | $4.0K | $208.0K | $134.0K | $292.0K | $0 | $0 |
| Net Income | -$101.6M | -$130.3M | -$101.7M | -$58.2M | -$52.0M | -$52.0M |
| EPS (Basic) | -$1.08 | -$1.23 | -$1.23 | -$0.94 | - | - |
| EPS (Diluted) | -$1.08 | -$1.23 | -$1.23 | -$0.94 | -$1.63 | - |
| Shares Outstanding | 107.7M | 102.2M | 88.2M | 87.5M | 40.4M | 31.9M |
| Operating Margin | -178.4% | -346.1% | -312.6% | -157.1% | -681.8% | - |
| Profit Margin | -162.8% | -309.7% | -278.5% | -157.2% | -678.8% | - |